Nicolas Praet

Johnson & Johnson, Belgium

Disclosure information not submitted.

Presentation(s):

• 5C-02 - Quantitative Bias Analysis to Assess Impact of Outcome Misclassification in a Claims-based COVID-19 Vaccine Safety Study in the US

  Tuesday, August 26, 2025
  8:45 AM - 9:00 AM ET

• 5C-03 - Evaluating the Safety Profile of the Janssen COVID-19 Vaccine (JCOVDEN): A VAC4EU post-authorization safety study

  Tuesday, August 26, 2025
  9:00 AM - 9:15 AM ET

• 5C-04 - An Observational Postauthorization Safety Study to Assess Adverse Events of Special Interest in Recipients of Ad26.COV2.S in the United States

  Tuesday, August 26, 2025
  9:15 AM - 9:30 AM ET